Cardiome tipping Merck $20M to settle tiff; Boehringer's Pradaxa bleeds hundreds of lawsuits;

@FiercePharma: AbbVie shares fall in first day of 'when-issued' trading. Story | Follow @FiercePharma

> Cardiome Pharma ($CRME) will pony up $20 million to Merck & Co. ($MRK) to settle issues over a heart drug they were partnering on. Story 

> Boehringer Ingelheim is now defending itself against hundreds of lawsuits tied to bleeding episodes, some fatal, in patients taking its blood thinner Pradaxa. Story

> Canadian company QLT has its last product for sale--an experimental treatment for a disease that can cause blindness--and it's valuing the product at $750 million. Item

> Indian officials expect the prices of 650 commonly used drugs to fall by up to 15% now that the government has set price controls. Story  

> Executives with two supermarkets in Lexington, KY, that cater to Hispanics admitted to smuggling drugs in from Mexico and selling them at their stores. Release

Medical Device News

 @FierceMedDev: Exact Sciences heads to the FDA with cancer diagnostic. Story | Follow @FierceMedDev

@MarkHFierce: MIT's Robert Langer is at it again--using porcupine quills as a model for next-generation medical device needles. More | Follow @MarkHFierce

 @DamianFierce: The effort to delay the medical device tax has picked up some Democratic support. Report | Follow @DamianFierce

> Japan's regulators approve Thoratec's HeartMate II pump. News

> India lures med tech manufacturing interest. Story

> Covidien's blood monitor will ship with GE's infant warmers. Item

Biotech News

 @FierceBiotech: GSK employs mobile phones to up vaccination rates in Africa. Story | Follow @FierceBiotech

@JohnCFierce: Sofinnova reaps $312M for its dedicated life sciences fund. Wished we saw more of these. News | Follow @JohnCFierce

> Teva chief Levin inks $376M deal on Xenon pain program. Article

> Isis grabs $31M in quick AstraZeneca cash during busy dealmaking round. Report

> Exclusive: Cerulean hauls in $13M, revs up deal talks as it nears PhIIb cancer data. News

Biotech Research News

> New molecule opens door to lymphoma combination therapy. News

> Seattle Genetics' next-gen antibody-drug conjugate tackles leukemia in the lab. Report

> Preclinical data snags GlaxoSmithKline's attention in $335M cancer immunotherapy deal. Article

> MicroRNAs could heal broken hearts. Item

Pharma Manufacturing News

> Novo selling Bangladeshi-made insulin after plant fires up. Story

> Congress investigating compounding pharmacy trade group. Item

> Endo reports oversized problem with oversized pain meds. Article

> Pharma files lawsuit against California drug-disposal law. News

And Finally... The consumer health side of GlaxoSmithKline ($GSK) has set up a smoking-cessation website to market products such as patches, lozenges and nicotine-laced gum. Item


Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.